DeepMed Research

Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Lymphoma
Leukemia
Myeloma

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Campath
Procedure: Stem Cell Transplant

First Posted Date: 2009-07-22

Last Posted Date: 2019-02-04

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT00943319

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Leukemia
Advanced Hematologic Malignancies
Preleukemia

Interventions: Drug: Clofarabine
Drug: Melphalan
Drug: Campath
Procedure: Stem Cell Transplant

First Posted Date: 2009-07-22

Last Posted Date: 2014-02-27

Lead Sponsor: University of Chicago

Target Recruit Count: 82

Registration Number: NCT00943592

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

Phase 1

Terminated

Conditions: Preleukemia
Myeloproliferative Disorders
Lymphoma
Myeloma
Graft Versus Host Disease

Interventions: Drug: Fludarabine
Drug: Melphalan
Drug: Campath

First Posted Date: 2009-07-22

Last Posted Date: 2014-03-17

Lead Sponsor: University of Chicago

Target Recruit Count: 1

Registration Number: NCT00943293

Locations: 🇺🇸
The Uniiversity of Chicago, Chicago, Illinois, United States

Combined Haploidentical-Cord Blood Transplantation for Adults and Children

Not Applicable

Completed

Conditions: Multiple Myeloma
Leukemia
Lymphoma
Myelodysplastic Syndrome

Interventions: Drug: Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)
Procedure: Stem Cell Transplant
Procedure: Stem Cells Collections
Drug: Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)
Drug: Fludarabine, Busulfan, and ATG

First Posted Date: 2009-07-22

Last Posted Date: 2021-01-27

Lead Sponsor: University of Chicago

Target Recruit Count: 87

Registration Number: NCT00943800

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Tolcapone Treatment of Pathological Gambling

Phase 2

Completed

Conditions: Pathological Gambling

Interventions: Drug: Tolcapone

First Posted Date: 2009-06-25

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 24

Registration Number: NCT00927563

Locations: 🇺🇸
Ambulatory Research Center, Minneapolis, Minnesota, United States

Delirium in Mechanically Ventilated Patients

Completed

Conditions: Delirium

First Posted Date: 2009-06-12

Last Posted Date: 2014-12-03

Lead Sponsor: University of Chicago

Target Recruit Count: 102

Registration Number: NCT00919698

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Pathways Linking Reduced Sleep Duration and Quality to Obesity Risk

Not Applicable

Completed

Conditions: Obesity
Diabetes

Interventions: Other: Baseline
Other: Sleep restriction
Other: Reduced Sleep Quality

First Posted Date: 2009-06-08

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 23

Registration Number: NCT00915707

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Sleep Disordered Breathing and Diabetes

Completed

Conditions: Type 2 Diabetes
Obstructive Sleep Apnea

First Posted Date: 2009-05-13

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 105

Registration Number: NCT00901472

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Docetaxel and cisplatin
Radiation: Docetaxel and cisplatin Plus Hypofractionated Radiotherapy

First Posted Date: 2009-04-23

Last Posted Date: 2013-12-06

Lead Sponsor: University of Chicago

Target Recruit Count: 11

Registration Number: NCT00887315

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Primary Care Patients With Depression for Internet-Based Social Support

Phase 1

Completed

Conditions: Depressive Disorder

Interventions: Behavioral: Simple Card
Behavioral: Patient Centered Brochure
Behavioral: Physician's endorsement

First Posted Date: 2009-04-23

Last Posted Date: 2012-12-17

Lead Sponsor: University of Chicago

Target Recruit Count: 49

Registration Number: NCT00886730

Locations: 🇺🇸
University of Chicago Physician's Group - PCG Maryland Avenue, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy